Kirk Lindstrom's  Instablog

One of my "explore portfolio" stocks, Antigenics Inc., (AGEN Charts) surged recently on positive survival data for its cancer drug Oncophage® (vitespen).

Charts don't show on instablogs with cut and paste so read the full article at:

Antigenics Surges on Oncophage Kidney Cancer Survival Data

As of today's close at $1.53, AGEN is up 219% YTD.
Click chart courtesy of stockcharts.com for full size image here

Interim survival data showed that patients with kidney cancer at intermediate risk of disease recurrence demonstrated an approximately 46% lower risk of death when treated with Oncophage® compared to the control group. Press Release

Disclaimer: I own and cover AGEN in "Kirk Lindstrom's Investment Letter" with my last buy below the current price as of this writing. I may sell or buy more shares without notice here but I will update my subscribers of any changes.

Doubled Money in a Down Market!

As of June 2, 2009, "Kirk's Newsletter Explore Portfolio" is up 8.4% YTD
vs. DJIA DOWN 0.4%    (More Info & FREE Sample Issue)

Originally poste at "Cisco Stock Testing Key Support Level" with charts and graphs that have been a problem getting to post here.

Cisco Systems (more CSCO charts) is testing its 200-day moving average (DMA) from above as the bulls and bears do battle over this key level. During bull markets, the 200 DMA is support while in a bear market, the 200-DMA is resistance.

Click chart courtesy of stockcharts.com for full size image

See article for chart

Quite often, after resistance changes to support, there is a test from above of the new support level before the stock takes off for big gains.

KEY bull/bear battle:

• If bullish, buy with a stop-loss below the 200 DMA for what you are willing to lose. If this is a new bull market, then the 200-DMA should become support rather than resistance.
   
• If bearish, this is a good place to unload before your expected decline to new lows just as the rally above the 200DMA in 2001 was a good place to get out above $20 before falling to $8 and change in 2002.

Click chart courtesy of stockcharts.com for full size image
See article for chart

I've traded Cisco in the past but I don't have a current position. I prefer other stocks (listed in Kirk Lindstrom's Investment Letter Explore Portfolio.) Also, I did so much buying of other stocks when the market was lower, that now I am looking to take some more profits rather than add more stocks.

Remember, the S&P500 (S&P500 charts) is up in the 900s from just recently being in the 600s. A correction could come out of nowhere at any time.

Click chart courtesy of stockcharts.com for full size image
See article for chart

The bears think this is a bear market rally before the market makes new lows. By taking some profits on what we bought at much lower levels, we have funds to buy again if the market corrects.

More information:

• More CSCO charts
• S&P500 charts
• World Stock Markets at a Glance

Since 12/31/98 "Kirk's Newsletter Explore Portfolio" is UP 107% (over a double!) vs. the S&P500 DOWN 11% vs. NASDAQ down 21% vs. Warren Buffett's Berkshire Hathaway (BRKA) up "only" 35% (All through 5/8/09) (More Info)

HURRY! Subscribe NOW and get the May 2009 Issue of "Kirk Lindstrom's Investment Newsletter" for FREE! !

YTD "Kirk's Newsletter Explore Portfolio" is UP 6.3% vs. the S&P500 UP 2.4% vs. DJIA down 2.6%

Below is today's press release from NanoViricides:

PRESS RELEASE: NanoViricides, Inc. Says Flu-Cide Drug Designed to Destroy All Influenza A Viruses Including Swine and Bird Flu

Already shown to be effective against diverse influenza subtypes such as H1N1 and different clades of H5N1

On Monday April 27, 2009, 7:00 am EDT

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that it is developing FluCide(™), its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown to be effective against both common influenza subtype H1N1, as well as two different variants of bird flu subtype H5N1.

The Company has previously announced excellent results in both animal studies and cell culture studies against widely different influenza subtypes and strains. If these results are confirmed in further animal and human studies, then FluCide would likely be considered the best ever drug effective against all influenzas. The Company is communicating its capabilities to various agencies involved in the current epidemic response.

The current swine flu outbreak is significant in that the H1N1 virus causing it is novel (http://www.cidrap.umn....). The US Department of Homeland Security has declared a Swine Flu Emergency yesterday. The WHO has said that the outbreak is an emergency of international concern (http://www.upi.com/Hea...). The pig is known to be a transitional species for influenza viruses. That means re-assortment (i.e. mixing) of genes from bird flu, human flu, and swine flu viruses can take place in pigs. This can lead to more lethal, drug resistant novel strains to emerge from different existing ones.

"Nanoviricides(™) have clear advantages over antibodies and vaccines as antiviral strategies," said Dr. Diwan, President of NanoViricides. Antibodies are relatively specific to a particular virus strain or subtype. It is well known that HIV and influenza viruses among many others, quickly escape antibodies. Vaccines depend upon the development of antibodies by the host, and thus, cannot protect efficiently against those viruses which are continually changing their character, such as the influenza virus. Influenza vaccines in particular have to be developed with the strain that is expected to infect in the next year’s cycle. It is well known that this is not a failure-proof strategy for epidemic-causing strains that are novel.

About NanoViricides:

NanoViricides, Inc. (nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements .... more here

Contact:

NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com

For commentary and my current outlook for NNVC, read "Kirk's Investment Newsletter"

Disclaimer: I own NNVC in my personal and newsletter accounts with the last shares bought at 80¢. I have targets to take profits on these in the newsletter and my personal account should my price objective be reached. I will not announce this ahead of time here.

• NNVC Charts
  
  
• FREE Sample Issue of "Kirk Lindstrom's Investment Letter"